Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial

Research output: Contribution to journalArticlepeer-review


  • Siow Ming Lee
  • Penella J Woll
  • Robin Rudd
  • Mary O'Brien
  • Stephen Spiro
  • Lindsay James
  • Kulsam Ali
  • Mark Jitlal
  • Allan Hackshaw

Colleges, School and Institutes


Cancer cells rely on angiogenesis for growth and dissemination, and small cell lung cancer (SCLC) is a highly angiogenic tumor. We evaluated thalidomide, an anti-angiogenic agent, when combined with chemotherapy and as maintenance treatment.


Original languageEnglish
Pages (from-to)1049-57
Number of pages9
JournalJournal of the National Cancer Institute
Issue number15
Publication statusPublished - 2009